ReViral
Stevenage Bioscience Catalyst
Gunnels Wood Road
Stevenage
Hertfordshire
SG1 2FX
United Kingdom
Website: http://www.reviral.co.uk/
Email: info@reviral.co.uk
About ReViral
ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion which will enter clinical trials in H2/2016.
YEAR FOUNDED:
2011
LEADERSHIP:
Founder and CSO: Stuart Cockerill
COO: Rachel Harland
CFO: Max Herrmann
CLINICAL TRIAL:
Please click here for clinical trial information.
19 articles about ReViral
-
Pfizer to Acquire ReViral and Its Respiratory Syncytial Virus Therapeutic Candidates
4/7/2022
Pfizer Inc. and ReViral Ltd. announced that the companies have entered into a definitive agreement under which Pfizer will acquire ReViral, a privately held, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus.
-
Andera Partners to sell its Life Sciences’ portfolio company ReViral to Pfizer
4/7/2022
Andera Partners announced today that Pfizer Inc. has entered into a definitive agreement to acquire Andera Life Sciences’ portfolio company ReViral Ltd.
-
Pfizer is taking a deeper dive into infectious disease with the acquisition of North Carolina-based ReViral, a biotech focused on developing therapeutics that target respiratory syncytial virus (RSV).
-
ReViral Appoints Brett Haumann as Chief Medical Officer
1/17/2022
ReViral Ltd. today announced that Brett Haumann, MD, has joined the company as Chief Medical Officer.
-
ReViral Announces Positive Recommendation by the Data Safety Monitoring Committee to Continue the Phase 2 Clinical Study of Sisunatovir for Treatment of Respiratory Syncytial Virus Infections in Hospitalized Infants
6/16/2021
ReViral Ltd.today announced the successful completion of Part A of the phase 2 clinical study of sisunatovir for the treatment of RSV infections in hospitalized infants (REVIRAL1). REVIRAL1 is a global three-part adapti
-
ReViral Raises $44 Million in Series C Financing
8/25/2020
ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. Additional investors participating in the financing include Andera Partners, Brace Pharma Capital, Green Sands E
-
ReViral Announces FDA Fast Track Designation Granted to Sisunatovir For The Treatment of Serious Respiratory Syncytial Virus Infection
8/4/2020
ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics that target respiratory syncytial virus, announced that the U.S. Food and Drug Administration has granted Fast Track designation to sisunatovir for the treatment of patients with serious RSV infection.
-
ReViral Announces Appointment of Alan Musso as Chief Financial Officer
10/21/2019
ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced the appointment of Alan A. Musso to the position of Chief Financial Officer, effective October 21, 2019
-
ReViral Appoints Alex C. Sapir as Chief Executive Officer
6/11/2019
ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019.
-
ReViral to Present Data Showing Absence of Clinical Resistance in Volunteers Infected with RSV then Treated with Sisunatovir (RV521)
5/14/2019
Highly encouraging resistance profile of Company’s lead drug candidate to be presented at the 32nd International Conference on Antiviral Research
-
ReViral Announces Grant of Key US Composition of Matter Patent for Their Respiratory Syncytial Virus Inhibitor Programme
4/8/2019
Patent claims RSV fusion protein inhibitors as medicines including lead pipeline candidate, RV521; patent nominally expires in 2035 (unextended)
-
BioSpace Movers and Shakers: March 1
3/1/2019
Pharma and biotech companies make changes to leadership roles, with new hires at Agios, Notable, Rapamycin, Confo, AVEO and more. -
ReViral Announces US$55 Million Series B Fundraising to Advance RSV Clinical Studies
8/1/2018
ReViral announced the successful completion of a US$55 million Series B financing.
-
London-based ReViral announced the completion of a Series B financing worth $55 million. The financing was jointly led by New Leaf Venture Partners and Novo Ventures, part of Novo Holdings, with new investors Perceptive Advisors. Existing investors also participated, including Andera Partners, Or...
-
Positive Results Achieved in ReViral’s Phase IIa RSV Challenge Study
2/5/2018
The study of RV521, an oral RSV fusion inhibitor, achieved all its primary and secondary endpoints (significantly reduced viral load, reduced total mucus weight and reduced clinical symptoms) compared to placebo.
-
ReViral Initiates Phase IIa Study Of RV521 For Treatment Of Respiratory Syncytial Virus
9/5/2017
-
ReViral Announces Good Safety And Pharmacokinetics From Phase I Programme For RSV Antiviral RV521 In Healthy Volunteers
4/24/2017
-
ReViral Initiates Phase 1 Clinical Trial Of Potent Oral Inhibitor Against Respiratory Syncytial Virus
10/31/2016
-
ReViral Announces Appointment Of New Chief Executive Officer
10/3/2016